Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification

Study Overview
=================
Brief Summary
-----------------
Patients with Systemic lupus erythematosus (SLE) are known to present an increased risk of osteoporosis and cardiovascular calcification. It has also been suggested that bone remodelling and cardiovascular calcification are regulated by the same mechanisms, but inversely in terms of calcium deposition, as osteoporosis is often associated with cardiovascular calcification. Inflammatory and immune factors have been implicated in these two processes. The role of the RANKL/OPG system in osteoclast differentiation has been elucidated over the last ten years. RANKL induces differentiation of monocytes-macrophages into osteoclasts, while, inversely, OPG exerts an inhibitory role by inactivating RANKL. Differentiation of smooth muscle cells into osteoblasts in the vessel wall induces calcification, and this phenomenon is counterbalanced by differentiation of monocytes into osteoclasts. Although the role of the RANKL/OPG ratio in the pathogenesis of osteoporosis has now been clearly established, its role in vascular calcification is only hypothetical at the present time. This study will focus on patients with SLE diagnosed and followed in the Amiens University Hospital Internal Medicine and Nephrology departments

Official Title
-----------------
Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification

Conditions
-----------------
Osteoporosis, Lupus Erythematosus, Systemic

Intervention / Treatment
-----------------
* Biological: RANKL/OPG ratio
* Device: bone densitometry
* Device: fan beam CT scan
* Device: Doppler ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women over 18 years old suffering from systemic lupus erythematosus. Exclusion Criteria: underlying diseases that can lead to bone and cardiovascular metabolic disturbances : Malignancies such as cancer metastasized Autoimmune disease other than LED or of overlap syndrome ( rhupus , MCTD ) Infection by HIV, hepatitis B and C Hepatic Cirrhosis Chronic renal failure Parathyroid disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Systemic lupus erythematosus<br>RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound | Biological: RANKL/OPG ratio<br> <br> Device: bone densitometry<br> <br> Device: fan beam CT scan<br> <br> Device: Doppler ultrasound<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RANKL/OPG ratio |  | Day 0 | 
| presence of osteoporosis |  | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiovascular calcification, RANK: Receptor Activator of Nuclear Factor kappa B, RANKL: Receptor Activator of Nuclear Factor kappa B Ligand, OPG: Osteoprotegerin, SLE: Systemic lupus erythematosus